Nalaganje...
The Value of Imaging and Composition-Based Biomarkers in Duchenne Muscular Dystrophy Clinical Trials
As the drug development pipeline for Duchenne muscular dystrophy (DMD) rapidly advances, clinical trial outcomes need to be optimized. Effective assessment of disease burden, natural history progression, and response to therapy in clinical trials for Duchenne muscular dystrophy are critical factors...
Shranjeno v:
| izdano v: | Neurotherapeutics |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Springer International Publishing
2019
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7007477/ https://ncbi.nlm.nih.gov/pubmed/31879850 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13311-019-00825-1 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|